BMS Completes $13.1-Bn Acquisition of MyoKardiaBy
Bristol-Myers Squibb (BMS) has completed its $13.1-billion acquisition of MyoKardia, a Brisbane, California-based clinical-stage biopharmaceutical company focused on cardiovascular diseases. BMS had announced the acquisition last month (October 2020).
MyoKardia’s lead drug candidate is mavacamten, in Phase III development, for treating obstructive hypertrophic cardiomyopathy (HCM), a chronic heart disease. A new drug application for mavacamten for treating symptomatic obstructive HCM is expected to be submitted to the US Food and Drug Administration in the first quarter of 2021. BMS says it expects to progress mavacamten in additional indications, including non-obstructive HCM, as well as develop two clinical-stage therapeutics: danicamtiv for treating genetic dilated cardiomyopathy, now in Phase II development, and MYK-224, in Phase I development, for treating HCM.
With the completion of the acquisition, MyoKardia is now a wholly owned subsidiary of Bristol Myers Squibb.
Source: Bristol-Myers Squibb